MYGN
Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.
Myriad Genetics, Inc. (MYGN) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Revisions (F). The rating has held at C for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.0) | C- (2.0) | B- (3.0) | B (3.3) | F (0.0) | C (2.3) |
| 2026-11-06 | B- (3.0) | C- (2.1) | B- (3.0) | B (3.2) | F (0.0) | C (2.3) |
| 2026-10-30 | B- (3.0) | C- (2.0) | B- (3.0) | B- (2.9) | F (0.0) | C (2.2) |
| 2026-10-23 | B- (3.0) | C- (2.0) | B- (3.0) | C (2.2) | F (0.0) | C- (2.1) |
| 2026-10-16 | B- (3.0) | C- (2.0) | B- (3.0) | D+ (1.6) | F (0.0) | C- (1.9) |